Central Bank & Trust’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Central Bank & Trust’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-14,117	Closed	-$10K	–	299
2020 Q4	$10K	Hold	14,117	–	–	﹤0.01%	253
2020 Q3	$32K	Hold	14,117	–	–	0.01%	216
2020 Q2	$50K	Hold	14,117	–	–	0.01%	181
2020 Q1	$53K	Sell	14,117 -16,579	-54%	-$54.6K	0.01%	173
2019 Q4	$92K	Buy	+30,696	New	+$79.8K	0.02%	164

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Central Bank & Trust's BMY.RT Position: Q1 2021 in Review

Central Bank & Trust sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 14,117 shares — an estimated $10K sold.

Central Bank & Trust first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $92K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Central Bank & Trust reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Central Bank & Trust sold 14,117 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $10K.
Central Bank & Trust first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Central Bank & Trust's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $92K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Central Bank & Trust's 13F filing for Q1 2021, filed 20 Apr 2021.